lncRNA- RP11-156p1.3, novel diagnostic and therapeutic targeting via CRISPR/Cas9 editing in hepatocellular carcinoma

Hebatalla Said Ali; Mariam Sameh Boshra; Mahmoud Shawky El Meteini; Ayman El-Sayed Shafei; Marwa Matboli

doi:10.1016/j.ygeno.2020.06.020

lncRNA- RP11-156p1.3, novel diagnostic and therapeutic targeting via CRISPR/Cas9 editing in hepatocellular carcinoma

Genomics. 2020 Sep;112(5):3306-3314. doi: 10.1016/j.ygeno.2020.06.020. Epub 2020 Jun 13.

Authors

Hebatalla Said Ali¹, Mariam Sameh Boshra¹, Mahmoud Shawky El Meteini², Ayman El-Sayed Shafei³, Marwa Matboli⁴

Affiliations

¹ The department of medicinal biochemistry and molecular biology, The school of Medicine, University of Ain Shams, Egypt.
² Department of General Surgery, the school of Medicine, University of Ain Shams, Abbassia, Cairo, Egypt.
³ Faculty of Medicine, Modern University for Technology & Information, Cairo, Egypt.
⁴ The department of medicinal biochemistry and molecular biology, The school of Medicine, University of Ain Shams, Egypt. Electronic address: drmarwa_matboly@med.asu.edu.eg.

PMID: 32544548
DOI: 10.1016/j.ygeno.2020.06.020

Abstract

We aim to characterize the expression of RNA panel in HCC. We assessed the expression of HCC-associated mRNA, miRNA and lncRNA network by real time PCR in sera and tissue samples. In a proof-of-principle approach, CRISPR cas9 mediated knock out for lncRNA- RP11-156p1.3 was performed in HEPG2 cell line to validate the role of the chosen RNA in HCC pathogenesis. The differential expression of RFTN1 mRNA, lncRNA- RP11-156p1.3 and miRNA-4764-5p was statistically different among the studied groups. After CRISPR cas9 mediated knockout of lncRNA- RP11-156p1.3 in HEPG2 cells, there was significant decrease in cell count and viability with reversal of the expression of the chosen RNAs. The chosen RNAs play a significant role in HCC pathogenesis and may be potential diagnostic and therapeutic targets.

Keywords: CRISPR cas9,Diagnosis; Hepatocellular carcinoma; Therapy; lncRNA; miRNA.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Biomarkers, Tumor / blood
Biomarkers, Tumor / genetics
Biomarkers, Tumor / metabolism
CRISPR-Cas Systems
Carcinoma, Hepatocellular / diagnosis
Carcinoma, Hepatocellular / genetics*
Carcinoma, Hepatocellular / metabolism
Carcinoma, Hepatocellular / therapy
Female
Gene Editing
Hep G2 Cells
Humans
Liver / metabolism
Liver Neoplasms / diagnosis
Liver Neoplasms / genetics
Liver Neoplasms / therapy
Male
Membrane Proteins / blood
Membrane Proteins / genetics
Membrane Proteins / metabolism
MicroRNAs / blood
MicroRNAs / metabolism
Middle Aged
RNA, Long Noncoding / blood
RNA, Long Noncoding / metabolism*
RNA, Messenger / blood
RNA, Messenger / metabolism

Substances

Biomarkers, Tumor
Membrane Proteins
MicroRNAs
RFTN1 protein, human
RNA, Long Noncoding
RNA, Messenger